Latest Market Pricing News

Meridian Energy's April 2025 report reveals a notable rise in hydro storage levels and a dip in national electricity demand, alongside a significant increase in generation prices.

Paladin Energy reports a 17% rise in quarterly uranium production and US$61 million in revenue, while recognizing a US$19.9 million inventory impairment. The company maintains strong liquidity and advances key projects in Namibia and Canada.

Envirosuite Limited has entered a binding Scheme Implementation Deed with UK-based Ideagen Limited, agreeing to a full acquisition at a significant premium. The transaction values Envirosuite at approximately A$132.2 million and awaits shareholder and regulatory approvals.

Contact Energy's April 2025 report reveals a slight decline in electricity and gas sales but improved netback prices, with mixed progress on key projects and rising generation costs.

Jameson Resources has released a 2025 feasibility update for its Crown Mountain Hard Coking Coal Project, confirming reserves and revealing a 200% increase in pre-tax NPV despite significant capital and operating cost inflation.

Macquarie Group Limited has announced a fully franked ordinary dividend of AUD 3.90 per share for the half-year ending March 2025, accompanied by a dividend reinvestment plan with no discount.

Sparc Technologies has launched a Share Purchase Plan offering eligible shareholders the chance to buy new shares at a 28.6% discount, aiming to raise up to $500,000 to fund key growth initiatives.

MedAdvisor Limited has received a non-binding offer from a major multinational software company to acquire its ANZ business division, valuing it above current market expectations.

Boss Energy reports a successful ramp-up to commercial production at its Honeymoon uranium mine, backed by a robust $229 million cash position and promising growth at its US Alta Mesa project.

Spheria Emerging Companies Limited has updated its dividend distribution approach, opting to use cash dividends to buy shares on-market due to the share price falling below its post-tax NTA per share on the ex-dividend date.

Proteomics International Laboratories Ltd is raising up to $5.5 million through a $4 million placement and a $1 million Share Purchase Plan at $0.37 per share, offering shareholders a discounted entry and free attaching options.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.